EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

3. Did the GLP-1 compounding lawsuits preserve a general right to continue supplying copies?

Dose Diligence research deskSection 01 · Page 3 of 34Last updated 17 Nov 2026

The appellate opinions retrieved do not support that conclusion. The Fifth Circuit affirmed judgments supporting FDA’s shortage determinations in the tirzepatide and semaglutide disputes. The tirzepatide opinion was filed August 27, 2026; the semaglutide opinion was revised September 1, 2026. (govinfo.gov)

A supplier saying that litigation protects its business should provide:

  • The case number and actual operative order.
  • The parties and activities covered.
  • Whether relief is preliminary, final, stayed or subsequently modified.
  • Counsel’s explanation of how the order applies to the proposed product and transaction.

Do not substitute a press release, pending complaint or appeal notice for an operative order. The published opinions reviewed are evidence of those decisions, not a comprehensive certification of every subsequent docket event.

Contract request: require prompt notice of any court or agency development affecting the supplier’s ability to perform, with suspension and transition rights that do not depend on proving a final violation.

Sources cited on this page

  1. govinfo.gov · Source 1 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
Section sources →